

## EFFECT OF EARLY TREATMENT WITH FLUVOXAMINE ON RISK OF EMERGENCY CARE AND HOSPITALIZATION AMONG PATIENTS WITH COVID-19: THE TOGETHER RANDOMIZED PLATFORM CLINICAL TRIAL

**Authors:** Gilmar Reis, MD<sup>1,2</sup>; Eduardo Augusto dos Santos Moreira Silva, MD<sup>1,2</sup>; Daniela Carla Medeiros Silva, MD<sup>1,2</sup>; Professor Lehana Thabane, PhD<sup>3</sup>; Aline Cruz Milagres, RN<sup>4,5</sup>; Thiago Santiago Ferreira, MD<sup>1</sup>; Castilho Vitor Quirino dos Santos<sup>1,2</sup>; Adhemar Dias de Figueiredo Neto, MD<sup>6</sup>; Eduardo Diniz Callegari, MD<sup>7</sup>; Leonardo Caçado Monteiro Savassi, MD<sup>2</sup>; Vitoria Helena de Souza Campos,<sup>1,2</sup> Ana Maria Ribeiro Nogueira, MD,<sup>9</sup> Ana Paula Figueiredo Guimaraes Almeida, MD,<sup>9</sup> Maria Izabel Campos Simplicio, BScPharm<sup>1</sup>; Luciene Barra Ribeiro, RN<sup>1</sup>; Rosemary Oliveira<sup>1</sup>; Ofir Harari, PhD<sup>4</sup>; Jamie I Forrest, MPH<sup>4</sup>; Hinda Ruton, MSc<sup>4</sup>; Sheila Sprague, PhD<sup>3</sup>; Paula McKay, MSc<sup>3</sup>; Alla V Glushchenko, MD,<sup>3</sup> PhD, Craig R. Rayner, PharmD, FRCP *Edin*<sup>10,11</sup>; Professor Eric J. Lenze, MD;<sup>12</sup> Angela M. Reiersen, MD<sup>12</sup>; Professor Gordon H. Guyatt, MD<sup>3</sup>; Professor Edward J. Mills, PhD, FRCP<sup>3</sup>; for the TOGETHER Investigators\*

*\*TOGETHER Investigators are listed in the supplementary materials*

### **Affiliations:**

1. Research Division, Cardresearch - Cardiologia Assistencial e de Pesquisa, Brazil
2. Department of Medicine, Pontifícia Universidade Católica de Minas Gerais, Brazil
3. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
4. Cytel Inc, Vancouver, British Columbia, Canada
5. Department of Public Health, Montes Claros State University, Brazil
6. Public Health Fellowship Program, Governador Valadares Public Health Authority, Brazil
7. Public Health, Mental and Family Medicine Department, Ouro Preto Federal University, Brazil
8. Public Health Care Division, City of Ibirité, Brazil
9. Public Health Division and Family Medicine, UNIFIP-MOC, City of Montes Claros, Brazil
10. Certara Inc. Princeton, New Jersey, USA
11. Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia
12. Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA

1    **Corresponding Authors:    Gilmar Reis MD, PhD**  
2                                    Director - Research Division  
3                                    CARDRESEARCH – Cardiologia Assistencial e de  
4                                    Pesquisa  
5                                    Associate Professor of Medicine  
6                                    Pontificia Universidade Católica de Minas Gerais  
7                    Address:    Rua Domingos Vieira 300, Sala 606 – Santa Efigenia  
8                                    Belo Horizonte – Minas Gerais  
9                                    Brazil – ZIP: 30.150-242  
10                    Email:     [greis@cardresearch.org](mailto:greis@cardresearch.org)  
11  
12                                    **Edward Mills PhD, FRCP**  
13                                    Professor  
14                                    Health Research Methods, Evidence & Impact  
15                                    McMaster University  
16                                    Hamilton, Ontario, Canada  
17                    Email:     [millsej@mcmaster.ca](mailto:millsej@mcmaster.ca)  
18                    Phone:     778 317 8530

19 ABSTRACT

20 **Background**

21 Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the  
22 TOGETHER randomized platform clinical trial for acutely symptomatic patients with COVID-  
23 19, we assessed the efficacy of fluvoxamine vs. placebo in preventing either extended emergency  
24 room observation or hospitalization due to COVID-19. Herein, we report the preliminary  
25 findings.

26 **Methods**

27 This placebo-controlled, randomized, adaptive, platform trial conducted among symptomatic  
28 Brazilian adults confirmed positive for SARS-CoV-2 included eligible patients with a known  
29 risk factor for progression to severe disease. Patients were randomly assigned to either  
30 fluvoxamine (100 mg twice daily for 10 days) or placebo. The primary endpoint was a  
31 composite outcome of emergency room observation for >6 hours or hospitalization from  
32 COVID-19 up to 28 days post randomization using intention to treat. Modified intention to treat  
33 (mITT) explored patients receiving at least 24 hours of treatment before a primary outcome  
34 event. Secondary outcomes included viral clearance at day 7, time to hospitalization, mortality,  
35 and adverse drug reactions. We used a Bayesian analytic framework to determine effects along  
36 with probability of success of intervention compared to placebo. The trial is registered at  
37 [clinicaltrials.gov](https://clinicaltrials.gov) (NCT04727424) and is ongoing.

38 **Findings**

39 The study team screened 9020 potential participants for this trial. The trial was initiated on June  
40 2, 2020, with the current protocol reporting randomization from January 15, 2021 to August 6<sup>th</sup>

41 2021, when the trial arms were stopped for superiority. A total of 3238 patients were allocated to  
42 fluvoxamine (n=739), placebo (n=733) and other treatments (n=1766). Herein, we report the  
43 effectiveness of fluvoxamine vs. a concurrent placebo control. The average age of participants  
44 was 50 years (range 18-102 years); 57% were female. The proportion of patients observed in an  
45 emergency room for >6 hours or admitted to hospital due to COVID-19 was lower for the  
46 fluvoxamine group compared to placebo (77/739 vs 108/733; Relative Risk [RR]: 0.71; 95%  
47 Bayesian Credible Interval [95% BCI]: 0.54 - 0.93), with a probability of superiority of 99.4%  
48 surpassing the prespecified superiority threshold of 97.6% (risk difference 4.3%). Of the  
49 composite primary outcome events, 88% were hospitalizations. Findings were similar for the  
50 mITT analysis (RR 0.68, 95% BCI : 0.50- 0.91). We found no significant relative effects  
51 between the fluvoxamine and placebo groups on viral clearance at day 7 (Odds ratio [OR]: 0.75;  
52 95% Confidence Intervals [95% CI]: 0.53 - 1.07), mortality (OR: 0.70; 95% CI: 0.36 - 1.30),  
53 time to death (Hazard ratio [HR]: 0.79; 95% CI: 0.58 - 1.08), days hospitalized (Mean Difference  
54 (MD) 1.22 days; 95% CI: 0.98 - 1.53), number of days ventilated (MD 1.10; 95% CI: 0.70 -  
55 1.73) or other secondary outcomes. Data capturing all 28 days of follow-up will be reported after  
56 August 26<sup>th</sup>, 2021.

## 57 **Interpretation**

58 Treatment with fluvoxamine (100 mg twice daily for 10 days) among high-risk outpatients with  
59 early diagnosed COVID-19, reduced the need for extended emergency room observation or  
60 hospitalization.

61 **Funding** The trial was supported by FastGrants and The Rainwater Foundation.

62

63 BACKGROUND

64 Although safe and effective vaccines for COVID-19 have been developed and distributed, there  
65 remain, particularly in low resource settings, major challenges regarding their production,  
66 allocation, and affordability.<sup>3</sup> Identifying inexpensive, widely available and effective therapies  
67 against COVID-19 is, therefore, of great importance. In particular, repurposing existing  
68 medicines that are widely available and with well understood safety profiles, has particular  
69 appeal.<sup>4</sup>

70 Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) and a Sigma-1 receptor  
71 (S1R) agonist.<sup>5</sup> There are several potential mechanisms for fluvoxamine in treatment of COVID-  
72 19 illness, including anti-inflammatory and possible antiviral effects.<sup>6</sup> A small placebo-  
73 controlled randomized trial has raised the possibility that fluvoxamine may reduce the risk of  
74 clinical deterioration in outpatients with COVID-19, suggesting the need for larger randomized,  
75 placebo-controlled studies.<sup>1,2</sup>

76 To evaluate the efficacy of fluvoxamine to prevent progression of COVID-19 and  
77 hospitalization among outpatients with laboratory-documented SARS-CoV-2, we conducted a  
78 randomized, placebo-controlled adaptive platform trial in Minas Gerais, Brazil. This flexible  
79 platform trial design allows for additional agents to be added and tested with standardized  
80 operating procedures outlined in a single overarching master protocol.<sup>7,8</sup> Among eight different  
81 interventions evaluated in this platform trial, we report here on the clinical evaluation of  
82 fluvoxamine using a concurrent placebo control group.

## 83 METHODS

### 84 ***Study design and oversight***

85 The TOGETHER Trial is a randomized adaptive platform trial to investigate the efficacy of  
86 repurposed treatments for COVID-19 disease among high-risk adult outpatients.<sup>9</sup> The trial was  
87 designed and conducted in partnership with local public health authorities from eleven  
88 participating cities in Brazil to simultaneously test potential treatments for early disease using a  
89 master protocol. A master protocol defines prospective decision criteria for discontinuing  
90 interventions for futility, stopping due to superiority against placebo, or adding new  
91 interventions. Interventions evaluated in the TOGETHER trial, thus far, include,  
92 hydroxychloroquine (protocol 1), lopinavir/ritonavir (protocol 1),<sup>10</sup> metformin, ivermectin,  
93 fluvoxamine, doxazosin and pegylated interferon lambda versus matching placebos (protocol 2).

94 The trial began on June 2, 2020 and enrollment into the fluvoxamine arm began on  
95 January 15<sup>th</sup> 2021. The trial, which complied with the International Conference of  
96 Harmonization – Good Clinical Practices, as well as local regulatory requirements, was approved  
97 for research ethics by local and national ethics boards in Brazil (CONEP CAAE:  
98 41174620.0.1001.5120, approval letter 5.501.284) and the Hamilton Integrated Research Ethics  
99 Board (HiREB, approval letter 13390) in Canada. The full protocol, statistical analysis plan, and  
100 additional details are appended in the web-appendix. The adaptive designs CONSORT extension  
101 (ACE) statement guided this trial report.<sup>16,17</sup> The steering committee made all protocol-related  
102 decisions and sponsors had no role in trial conduct, data analysis or decision to submit  
103 manuscript for publication. An independent Data Safety Monitoring Committee (DSMC)  
104 provided trial oversight.

105

## 106 **Setting**

107 The appended web-appendix lists the cities and investigators of the eleven clinical sites in Brazil  
108 that participated in the trial. Local investigators, in partnership with local public health  
109 authorities, recruited participants at community health facilities (emergency settings, flu-  
110 symptom referral centers, primary care community centers). We used several community  
111 outreach strategies including physical and social media as per local public health authorities, in  
112 order to create awareness of the trial.

## 113 **Participant Screening**

114 Upon presentation to one of the trial outpatient care clinics, local investigators screened potential  
115 participants to identify those who met the eligibility criteria.

116 The key inclusion criteria were: 1) patients over the age of 18, 2) presenting to an  
117 outpatient care setting with an acute clinical condition consistent with COVID-19 and symptoms  
118 beginning within 7 days of the screening date, 3) positive rapid test for SARS-CoV-2 antigen  
119 performed at the time of screening or patient with positive SARS-CoV-2 diagnostic test within 7  
120 days of symptom onset, 4) at least one additional criterion for high-risk: diabetes mellitus;  
121 systemic arterial hypertension requiring at least one oral medication for treatment; known  
122 cardiovascular diseases (heart failure, congenital heart disease, valve disease, coronary artery  
123 disease, cardiomyopathies being treated, clinically manifested heart disease and with clinical  
124 repercussion); symptomatic lung disease and / or being treated (emphysema, fibrosing diseases);  
125 symptomatic asthma patients requiring chronic use of agents to control symptoms; smoking;  
126 obesity, defined as  $BMI > 30 \text{ kg} / \text{m}^2$  (weight and height information provided by the patient);  
127 transplant patients; patient with stage IV chronic kidney disease or on dialysis;  
128 immunosuppressed patients / using corticosteroid therapy (equivalent to at least 10 mg of

129 prednisone per day) and / or immunosuppressive therapy; patients with a history of cancer in the  
130 last 0.5 years or undergoing current cancer treatment, or age  $\geq$  50 years; and unvaccinated status.

131 Patients who met any of the following criteria were excluded from the trial: 1) Diagnostic  
132 examination for SARS-CoV2 negative associated with acute flu-like symptoms (patient with  
133 negative test taken early and becoming positive a few days later were eligible, if he/she was  $<$ 7  
134 days after the onset of flu-like symptoms); 2) Acute respiratory condition compatible with  
135 COVID-19 treated in the primary care and previously requiring hospitalization; 3) Acute  
136 respiratory condition due to other causes; 4) Received vaccination for SARS-CoV2; 5) Dyspnea  
137 secondary to other acute and chronic respiratory causes or infections (e.g., decompensated  
138 COPD, acute bronchitis, pneumonia, primary pulmonary arterial hypertension); 6) Current use of  
139 selective serotonin reuptake inhibitors; uncontrolled psychiatric disorders; or suicidal ideation; 7)  
140 Inability or unwillingness to follow research guidelines and procedures. A full list of exclusion  
141 criteria are provided in the trial protocol.

142 If a patient met the above eligibility criteria, study personnel obtained written informed  
143 consent. After obtaining informed consent a rapid antigen test for COVID-19 (Panbio®, Abbott  
144 laboratories) and a pregnancy test for women of childbearing age were performed. If the  
145 COVID-19 test was negative or if the pregnancy test was positive, the participant was not  
146 included in the trial. After informed consent, study personnel collected the following data prior  
147 to randomization: demographics, medical history concomitant medications, co-morbidities,  
148 exposure to Index Case information, WHO clinical worsening scale, and the PROMIS Global  
149 Health Scale.



150 ***Randomization and Trial Interventions***

151 Participants were randomized using a centralized core randomization process handled by an  
152 independent unblinded pharmacist who was not aware of any protocol-related procedures and  
153 contracted specifically for this process. Sites requested randomization by text message to the  
154 pharmacist at the coordinating center. This maintained concealment of allocation. Patients were  
155 randomly assigned using a block randomization procedure for each participating site, stratified  
156 by age (< 50 years /  $\geq$  50 years). The trial team, site staff and patients were blinded to treatment  
157 allocation. The active drugs and the placebo pills were packaged in identically shaped bottles and  
158 labeled with alphabet letters corresponding to the active arm or placebo arm. Only the third-party  
159 pharmacist responsible for releasing the randomization was aware of which letter was associated  
160 with which drug and/or placebo. As this is a multi-arm trial and all active interventions have a  
161 matching inert placebo, the matching placebo represents the proportion of the control group for  
162 the number of arms in the trial at any given time.

163 ***Data Collection and Participant Follow-Up***

164 Our primary outcome is a composite that includes emergency room visits due to the clinical  
165 worsening of COVID-19 (defined as participant remaining under observation for > 6 hours) or  
166 hospitalization due to the progression of COVID-19 (worsening of clinical status) and/or  
167 suspected COVID-19 complications within 28 days of randomization. Key secondary outcomes  
168 include: 1) viral clearance, 2) time to clinical improvement, 3) number of days with respiratory  
169 symptoms, 4) time to hospitalization for any cause or due to COVID-19 progression, 5) all-cause  
170 mortality and time to death from any causes, 7) WHO clinical worsening scale score, 8) days in  
171 hospital and on ventilator and 9) adverse events, adverse reactions to the study medications and

172 the proportion of participants who are non-adherent with the study drugs. All secondary  
173 outcomes are assessed up to 28 days following randomization.

174 Study personnel collected, via in person, telephone contact and social media applications  
175 using video-teleconferencing, outcome data on days 1, 2, 3, 4, 5, 7, 10, 14, and 28. We collected  
176 outcome data irrespective of whether participants took study medication. In case of adverse  
177 events, unscheduled visits (during the treatment period) outside of clinical care could occur at  
178 any time.

179 Considering the transmissible characteristic of SARS-CoV-2 and the isolation  
180 recommendations of positive individuals, we collected limited vital sign data. Cardiac safety was  
181 assessed using a 6-lead ECG (Kardiamobile, Mountain View, CA) at the baseline visit. The  
182 digital recordings were de-identified and transferred to a central facility (Cardresearch, Belo  
183 Horizonte, Brazil) for reading. Oxygen status was assessed using a pulse oximeter for non-  
184 invasive arterial oxygen saturation (SpO<sub>2</sub>) and pulse (Jumper Medical Equipment, Shenzhen,  
185 China), and temperature using a standard digital oral thermometer administered by research  
186 personnel. Mid-turbinate nasal swab kits and sterile recipient storage were provided for  
187 collection of nasopharyngeal swab or sputum/saliva. They were performed by the first quarter of  
188 participants enrolled in the trial at days 3 and 7. PCR of viral clearance was assessed to  
189 determine if active drugs demonstrate any anti-viral effects.

190 All serious and non-serious adverse events were reported to study personnel as per local  
191 regulatory requirements. Reportable adverse events included serious adverse events, adverse  
192 events resulting in study medication discontinuation, and adverse events assessed as possibly  
193 related to study medication.

194 ***Trial interventions***

195 All participants received usual standard care for COVID-19 provided by healthcare professionals  
196 workers at public health facilities. Patients were randomized to fluvoxamine (Luvox ®, Abbott)  
197 at a dose of 100 mg twice a day for 10 days or corresponding placebo starting right after  
198 randomization (day 1). Research personnel provided participants a welcome video with  
199 information on trial, study drug, adverse events and follow-up procedures. Clinicians providing  
200 usual care in public health facilities typically focus on the management of symptoms and with  
201 antipyretics, and recommend antibiotics only if they suspect bacterial pneumonia.

202 ***Statistical Analyses***

203 The Adaptive Design Protocol and the Master Statistical Analysis Plan provide details of sample  
204 size calculation and statistical analysis (appended). This trial is adaptive and applies sample size  
205 re-estimation approaches. To plan for each arm, we assumed a minimum clinical utility of 37.5%  
206 (relative risk reduction) to achieve 80% power with 0.05 two-sided Type 1 error for a pairwise  
207 comparison against the placebo (talc) assuming a control event rate (CER) of 15%. This resulted  
208 in an initial plan to recruit 681 participants per arm. The statistical team conducted planned  
209 interim analyses. Stopping thresholds for futility were established if the posterior probability of  
210 superiority was less than 40% at interim analysis. An arm can be stopped for superiority if the  
211 posterior probability of superiority meets the threshold of 97.6%

212 Baseline characteristics are reported as count (percent) or median and interquartile range  
213 (IQR) for continuous variables. We applied a Bayesian framework for our primary outcome  
214 analysis and a frequentist approach for all sensitivity analyses and secondary outcomes. Posterior  
215 efficacy of fluvoxamine for the primary outcome is calculated using the beta-binomial model for

216 event rates, assuming informed priors based on the observational data for both placebo and  
217 fluvoxamine, for both Intention-to-Treat (ITT), modified ITT (defined as receiving the study  
218 drug for at least 24 hours before an event) and Per-Protocol (PP) analyses (defined as taking  
219 >80% of possible doses). Modified ITT was defined as receiving treatment for at least 24 hours  
220 before a primary outcome. We accounted for any temporal changes in events rates by using only  
221 the concurrent randomised population. We assessed subgroup effects according to the preplanned  
222 statistical analysis plan. We calculated the number needed to treat.

223         Secondary outcomes were assessed using a pre-specified frequentist approach. For viral  
224 clearance we fitted a longitudinal, mixed-effect logistic regression model with a treatment and  
225 time interaction term for binary patient outcomes (Covid-19 positive/negative) reported on day 3  
226 and 7 from randomization, with subject random effect. We assessed time-to-event outcomes  
227 using Cox proportional hazard models and binary outcomes using logistic regression. Per  
228 protocol analyses were considered sensitivity analyses to assess the robustness of the results. All  
229 analyses were performed using R version 4.0.3. Full details of the Statistical Analysis Plan  
230 (SAP) are appended.

### 231 **Data and Safety Monitoring Committee**

232 A Data and Safety Monitoring Committee provided independent oversight for this trial. We  
233 planned a 4<sup>th</sup> interim analysis of the fluvoxamine arm with data collected up to August 2<sup>nd</sup>, 2021.

### 234 **Role of the funding source**

235 The funders had no role in the study design, data collection, analysis, interpretation or writing, or  
236 decision to submit for publication. The executive committee take responsibility for the integrity  
237 of the data and the accuracy of the data analysis. The trial executive committee oversaw all  
238 aspects of trial conduct, completeness, data accuracy and adherence of trial conduct to the

239 protocol and the committee vouch for the accuracy and completeness of the data and for fidelity  
240 to the protocol.

241

## 242 RESULTS

243 We screened 9020 potential participants for inclusion in this trial to date. The trial enrolled its  
244 first participant on June 2, 2020 and enrolment into the fluvoxamine arm began on January 20,  
245 2021. By August 6, 2021, 1,472 recruited participants were randomized to fluvoxamine (n= 739)  
246 or the placebo (n=733), and 1,766 were randomized to other treatment arms (Figure 1). The  
247 median age was 50 years (range 18-102) and 846 (57.5%) were women (Table 1). Most  
248 participants self-identified as mixed-race 1,403 (95.3%), 11 (0.7%) as white, 10 (0.7%) as black  
249 or African American, the rest self-identified as unknown 48 (3.3%). As the trial is ongoing,  
250 herein we provide descriptive summaries of only those randomized to fluvoxamine and its  
251 concurrent control. With respect to covariates of age, BMI, and co-morbidities, the groups were  
252 generally well balanced (Table 1). The mean number of days with symptoms prior to  
253 randomization was 4 days (Standard Deviation 1.76).

### 254 **Primary Outcomes**

255 The Data Safety Monitoring Committee met four times since the protocol initiation and last met  
256 on August 5, 2021, recommending that the TOGETHER Trial stop randomizing patients to the  
257 fluvoxamine arm, as this comparison had met the pre-specified superiority criterion for the  
258 primary endpoint (prespecified superiority threshold 97.6%). Based on the Bayesian beta-  
259 binomial model, there was evidence of a benefit of fluvoxamine reducing hospitalization or  
260 observation in an emergency room for greater than six hours due to COVID-19 (Relative Risk

261 [RR]: 0.71; 95% Bayesian Credible Interval [BCI]: 0.54 - 0.93) in the Intention-to-Treat (ITT)  
262 population (figure 2A) and (RR: 0.68; 95% BCI: 0.50 - 0.91) in a modified ITT population  
263 (figure 2B). The probability that the event rate was lower in the fluvoxamine group compared to  
264 placebo was 99.4% for the ITT population, and 99.6% for the modified ITT population (Figure  
265 2A/B). These posterior efficacy numbers were higher than the pre-specified 97.6% threshold set  
266 for the fourth interim analysis. In the fluvoxamine group 77 (10.4%) participants experienced a  
267 primary outcome event compared to 108 (14.7%) in the placebo group (Table 2). Most events  
268 (88%) were hospitalizations. The number needed to treat is 24. Per protocol analysis  
269 demonstrated a larger treatment effect (0.34, 95% BCI, 0.20-0.54).

#### 270 *Secondary Outcomes*

271 Table 3 presents findings from secondary outcome analyses. There were no significant  
272 differences between fluvoxamine and placebo for viral clearance at Day 7 (p=0.18) and eFigure3  
273 in web-appendix, hospitalizations due to COVID (p=0.17), all-cause hospitalizations (p=0.12),  
274 time to hospitalization (p=0.14, number of days in hospital (p=0.07), mortality (p=0.26), time to  
275 death (p=0.26), number of days on mechanical ventilation (p=0.67), time to recovery (p=0.86) or  
276 the PROMIS Global Health Scale (p=0.44). With respect to adverse events, there were  
277 significantly greater number of Grade 1 (mild) treatment emergent adverse events (TEAE)  
278 among patients in the fluvoxamine arm (p<0.01). However, no differences between fluvoxamine  
279 and placebo were observed for TEAEs of Grades 2, 3, 4, or 5.

#### 280 *Sub-group Analyses*

281 In the prespecified subgroup analysis, we found no evidence of moderation of treatment effect  
282 for fluvoxamine compared to placebo, for sub-groups of age, sex, days since symptom onset, or  
283 co-morbidities (Figure 3 and web-appendix eTable 1).

284

## 285 DISCUSSION

286 This is the first large randomized controlled trial to test the efficacy of fluvoxamine for acute  
287 treatment of COVID-19. We found a clinically important absolute risk reduction of 4.3%, and  
288 29% relative risk reduction, on the primary outcome of retention in an emergency setting for  
289 COVID-19 disease observation or hospitalization, consequent on the administration of  
290 fluvoxamine for 10 days. This study is only the 2<sup>nd</sup> study to demonstrate an important treatment  
291 benefit for a repurposed drug in the early treatment population.<sup>11</sup> Our findings represent the latest  
292 interim analysis of the trial resulting in the DSMC recommending stopping the active  
293 fluvoxamine arm. The final analysis from the trial, wherein all patients have contributed 28 days  
294 of follow-up data, will be made available 28 days after the last randomized patient has completed  
295 this period (August 25, 2021). Given fluvoxamine's safety, tolerability, ease of use, low cost, and  
296 widespread availability, these findings may have influence on national and international  
297 guidelines on the clinical management of COVID-19.

298

### 299 **Comparison with prior evidence**

300 Our results are consistent with an earlier smaller trial conducted in the United States (led by EJJ  
301 and AMR).<sup>2</sup> That study used a higher dose of fluvoxamine (100mg tid for 15 days) and included  
302 a lower risk group for the primary outcome but found no clinical deterioration among 80 patients  
303 receiving fluvoxamine vs. 6 of 72 patients receiving placebo. A large observational study from

304 France involved a different population, 7230 hospitalized COVID-19 patients, and reported a  
305 reduction in use of intubation or death with use of SSRIs.<sup>1</sup>

306 The underlying mechanism of fluvoxamine for COVID-19 disease remains uncertain. Although  
307 hypotheses include several potential mechanisms,<sup>6</sup> the main reason for the initial study of  
308 fluvoxamine as a treatment of COVID-19 was its anti-inflammatory action through activation of  
309 the  $\sigma$ -1 receptor (S1R).<sup>12</sup> S1R is an endoplasmic reticulum (ER) chaperone membrane protein  
310 involved in many cellular functions,<sup>13</sup> including regulation of ER stress response/unfolded  
311 protein response and regulation of cytokine production in response to inflammatory triggers.<sup>14</sup> In  
312 the presence of fluvoxamine, S1R may prevent the ER stress sensor Inositol-Requiring Enzyme  
313 1 $\alpha$  (IRE1) from splicing and activating the mRNA of X-Box Protein 1 (XBP1), a key regulator  
314 of cytokine production including IL-6, IL-8, IL-1 $\beta$  and IL-12. In a 2019 study by Rosen and  
315 colleagues, fluvoxamine showed benefit in preclinical models of inflammation and sepsis  
316 through this mechanism.<sup>14</sup>

317 Another mechanism may be fluvoxamine's anti-platelet activity.<sup>15</sup> SSRIs can prevent loading of  
318 serotonin into platelets and inhibit platelet activation, that may reduce the risk of thrombosis, and  
319 these antiplatelet effects can be cardioprotective. In vitro and animal studies are needed to help  
320 clarify the most likely mechanism(s). Biomarker studies included as part of future RCTs may  
321 also help to clarify mechanisms.

322

### 323 **Strengths and limitations**

324 Since the start of the COVID-19 pandemic, there have been more than 2800 RCTs registered on  
325 clinicaltrials.gov. However, less than 300 have been reported and the vast majority of clinical  
326 trials have been small and underpowered, with sample sizes less than 100. In many cases, these



327 trials have been unsuccessful at recruiting as the local epidemics occur in waves and sustainable  
328 infrastructure to maintain staff or local interest for recruitment is lacking. The trials that provide  
329 the clearest medical understanding tend to be the larger platform trials, such as SOLIDARITY,<sup>16</sup>  
330 RECOVERY,<sup>17</sup> PRINCIPLE,<sup>11</sup> and REMAP-CAP.<sup>18</sup> As a result, we actively collaborate with  
331 other investigators running trials with overlapping interventions so that they can be aware of our  
332 study decisions and determine whether they should influence their respective trials.

333 Major strengths include the rapid recruitment and enrolment of high-risk patients for the  
334 development of severe COVID-19. Our recruitment strategy involves the engagement with the  
335 local public health system, thus allowing recruitment that frequently exceeds twenty patients per  
336 day. We enrolled only participants with diagnosed COVID-19 and less than 7 days of symptom  
337 onset using a commercially available COVID-19 AG rapid test (Panbio ®). The concordance of  
338 COVID-19 positive tests with RT-PCR was evaluated on the group of participants with PCR  
339 evaluations and found a concordance rate of > 99% on both tests collected at baseline.

340 Our understanding of the epidemiology of COVID-19 as well as its disease progression and  
341 outcomes have evolved since beginning this platform trial in June 2020. Early studies assessed  
342 the effects of interventions of viral load and clearance, while later studies also evaluate more  
343 clinical outcomes. We made adjustments to the trial according to prespecified rules and in  
344 communication with the appropriate ethics review committees that allowed us to respond to the  
345 epidemic waves while maintaining high rates of recruitment. Unlike many outpatient clinical  
346 trials, our study involves direct patient contact through the use of medical students, nurses and  
347 physicians who do at-home visits as well as follow-up via telecommunications. Given the rapid  
348 recruitment of patients in combination with the high event rate of emergency room visits and  
349 hospitalizations, we were able to evaluate the effects of interventions when portions of the

350 planned population had been recruited. The period of time between first recruitment of a patient  
351 on fluvoxamine and the data cut for our trial was 197 days. Our trial assessed a primary outcome  
352 as a binary event having occurred by 28 days post-randomization.

353 One of the major limitations of our fluvoxamine trial is primarily related to the challenges of  
354 conducting a trial in a disease that is not well characterized. Currently, there is no standard of  
355 care that exists for early treatment of COVID-19 and various advocacy groups promote different  
356 interventions, including some of those evaluated in this and our previous trials. Furthermore,  
357 there is little understanding of who is at greatest risk of disease progression from this disease as  
358 some patients with numerous risk factors do recover quickly while some others with less  
359 established risk factors may not. Our population had a higher rate of hospitalization events than  
360 observed in most clinical trials, thus permitting inferences on treatment effects in this higher-risk  
361 population.

362

### 363 **Implications**

364 Our trial has found that fluvoxamine, an inexpensive existing drug, reduces the need for  
365 advanced disease care in this high-risk population. A ten-day course of fluvoxamine costs  
366 approximately \$4 even in well-resourced settings.<sup>19</sup> Our study compares favorably and exceeds  
367 the treatment effects of more expensive treatments including monoclonal antibodies for  
368 outpatient treatment.<sup>20,21</sup> The absolute number of serious adverse events associated with  
369 fluvoxamine was lower than our placebo group and this might reflect the modulatory effect of  
370 fluvoxamine on systemic inflammation in these participants. Lower respiratory tract infections  
371 were reported less frequently in patients in the fluvoxamine group than those in the placebo  
372 group. This is concordant with the reduction of hospital admissions in patients with confirmed

373 COVID-19 treated with fluvoxamine, and the numerically lower number of patients requiring  
374 mechanical ventilation.

375

376 Fluvoxamine is widely available but is not on the WHO Essential Medicines List,<sup>22</sup> whereas a  
377 closely related SSRI fluoxetine is on the list. It is now of critical importance to determine  
378 whether a class-effect exists and whether these drugs can be used interchangeably for COVID-  
379 19. The recent important findings that inhaled budesonide increased time to recovery among a  
380 similar population as our trial and had a trend towards decreased hospitalizations suggests this as  
381 an alternative or additional intervention for outpatient care that should be evaluated. The  
382 PRINCIPLE trial evaluated time to recovery using self-reported recovery up to 28 days after  
383 randomization to budesonide.<sup>11</sup> Our trial differed as we evaluated improvement in the WHO  
384 categorization of disease disability up to days 14 and then 28 (web-appendix eFigure 2). Finally,  
385 our study was among unvaccinated patients. Further evidence of treatment benefits are needed to  
386 determine the effect of fluvoxamine among vaccinated populations.

387 Use of interventions, including fluvoxamine, to prevent progression of illness and hospitalization  
388 is critically dependent on identifying higher risk individuals. Unselected populations will have a  
389 lower risk. What absolute reduction in risk of clinical deterioration would motivate patients to  
390 choose treatment (probably the >4% we observed, but perhaps not much lower) remains  
391 uncertain. These considerations raise the importance of the development of a validated  
392 prediction rule for deterioration in patients in the early stages of COVID-19 infection.

### 393 **Conclusion**

394 Administration of fluvoxamine reduced the rate of prolonged observation in an emergency care  
395 setting or hospitalization due to COVID-19 in people with a high risk of serious disease.

396

397

398

399

400

401

402

403

404

405

406

407 **ACKNOWLEDGEMENTS**

408 The trial was supported by FastGrants and the Rainwater Foundation. GR and EJM had full  
409 access to all the data in the study and take responsibility for the integrity of the data and the  
410 accuracy of the data analysis. Our research network consists of partnerships between academics  
411 and clinicians at McMaster University in Ontario, Canada, and Pontificia Universidade Catolica  
412 de Minas Gerais, Claros State University, and University of Ouro Preto in Minas Gerais, Brazil.  
413 Other partners include Cytel, Platform Life Sciences, MMS Holdings, WHO Therapeutic  
414 Guidelines Committee, and the Society for Clinical Trials. Trial documents are found on the  
415 Open Science Framework (<https://doi.org/10.17605/OSF.IO/EG37X>). Trial data are shared with  
416 the International COVID-19 Data Alliance (ICODA). The work has been presented and reviewed  
417 by the WHO Platform Trials Group.

418 **Data Safety and Monitoring Committee (DSMC) Members:** William Cameron, University of  
419 Ottawa (Canada), James Orbinski, York University (Canada), Sonal Singh, University of  
420 Massachusetts (USA), Kristian Thorlund, McMaster University (Canada), Jonas Haggstrom of  
421 Cytel Inc. (Sweden).

422

423

424

425 **REFERENCES**

426

- 427 1. Hoertel N, Sánchez-Rico M, Vernet R, et al. Association between antidepressant use and  
428 reduced risk of intubation or death in hospitalized patients with COVID-19: results from an  
429 observational study. *Mol Psychiatry* 2021. <https://www.nature.com/articles/s41380-021-01021-4>
- 430 2. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs Placebo and Clinical  
431 Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. *JAMA*  
432 2020; **324**: 2292-300.
- 433 3. Torres I, Artaza O, Profeta B, Alonso C, Kang J. COVID-19 vaccination: returning to  
434 WHO's Health For All. *Lancet Glob Health* 2020; **8**: e1355-e6.
- 435 4. Rayner CR, Dron L, Park JJH, et al. Accelerating Clinical Evaluation of Repurposed  
436 Combination Therapies for COVID-19. *Am J Trop Med Hyg* 2020; **103**: 1364-6.
- 437 5. Omi T, Tanimukai H, Kanayama D, et al. Fluvoxamine alleviates ER stress via induction  
438 of Sigma-1 receptor. *Cell Death Dis* 2014; **5**: e1332.
- 439
- 440 6. Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxamine: A Review of  
441 Its Mechanism of Action and Its Role in COVID-19. *Front Pharmacol*. 2021;12:652688. doi:  
442 10.3389/fphar.2021.652688
- 443 7. Park JJH, Siden E, Zoratti MJ, et al. Systematic review of basket trials, umbrella trials,  
444 and platform trials: a landscape analysis of master protocols. *Trials* 2019; **20**: 572.
- 445 8. Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple  
446 Diseases, or Both. *N Engl J Med* 2017; **377** 62-70.
- 447 9. Reis G, Silva EAdSM, Silva DCM, et al. A multi-center, adaptive, randomized, platform  
448 trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease  
449 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol. *Gates*  
450 *Open Research* 2021; **5**: 117.
- 451 10. Reis G, Moreira Silva E, Medeiros Silva DC, et al. Effect of Early Treatment With  
452 Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients  
453 With COVID-19: The TOGETHER Randomized Clinical Trial. *JAMA Netw Open* 2021; **4**:  
454 e216468.
- 455
- 456 11. Yu L-M, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at  
457 high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled,  
458 open-label, adaptive platform trial. *The Lancet*. DOI:[https://doi.org/10.1016/S0140-6736\(21\)01744-X](https://doi.org/10.1016/S0140-6736(21)01744-X)  
459
- 460 12. Nicol GE, Karp JF, Reiersen AM, Zorumski CF, Lenze EJ. "What Were You Before the  
461 War?" Repurposing Psychiatry During the COVID-19 Pandemic. *J Clin Psychiatry* 2020; **81**.


- 462 13. Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1  
463 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. *Eur J Pharmacol*  
464 2014; **727**: 167-73.
- 465 14. Rosen DA, Seki SM, Fernández-Castañeda A, et al. Modulation of the sigma-1 receptor-  
466 IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. *Sci Transl Med*  
467 2019; **11**.
- 468 15. Schlienger RG, Meier CR. Effect of selective serotonin reuptake inhibitors on platelet  
469 activation: can they prevent acute myocardial infarction? *Am J Cardiovasc Drugs* 2003; **3**: 149-  
470 62.
- 471 16. Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed Antiviral Drugs for Covid-19 -  
472 Interim WHO Solidarity Trial Results. *N Engl J Med* 2021; **384**: 497-511.
- 473 17. Horby PW, Pessoa-Amorim G, Peto L, et al. Tocilizumab in patients admitted to hospital  
474 with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label,  
475 platform trial. *medRxiv* 2021: 2021.02.11.21249258.
- 476 18. Angus DC, Derde L, Al-Beidh F, et al. Effect of Hydrocortisone on Mortality and Organ  
477 Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid  
478 Domain Randomized Clinical Trial. *JAMA* 2020; **324**: 1317-29.
- 479 19. Wang J, Levi J, Ellis L, Hill A. Minimum manufacturing costs, national prices and  
480 estimated global availability of new repurposed therapies for COVID-19. *medRxiv* 2021.  
481 **doi:** <https://doi.org/10.1101/2021.06.01.21258147>
- 482 20. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in  
483 Outpatients with Covid-19. *N Engl J Med* 2021; **384**: 229-37.
- 484 21. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing  
485 Antibody Cocktail, in Outpatients with Covid-19. *N Engl J Med* 2021; **384**: 238-51.
- 486 22. World Health Organization model list of essential medicines: 21st list 2019: World  
487 Health Organization, 2019.  
488 <https://www.who.int/publications/i/item/WHOMVPEMPIAU2019.06>

489

490

491 **TABLES & FIGURES**

Figure 1: Participant Flowchart




492  
493  
494  
495  
496  
497  
498  
499



500 **Figure 2:** Probability of efficacy and Bayesian relative risk of extended emergency room  
501 observation or hospitalization for fluvoxamine vs. placebo (Panel A: ITT population; Panel B:  
502 Modified ITT population)

503 A) *Intention-to-treat analysis*



504


505

506

507

508 B) *Modified intention-to-treat analysis*


509



510

511 **Figure 3: Sub-group analyses of fluvoxamine vs. placebo in the TOGETHER Trial**

512



513

514 **Table 1.** Patient characteristics by treatment allocation in the TOGETHER Trial

	<b>Fluvoxamine</b> <b>(n=739)</b>	<b>Placebo</b> <b>(n=733)</b>	<b>Total</b> <b>(n=1472)</b>
<b>Sex</b>			
Female	408(55.2)	438(59.8)	846(57.5)
Male	331(44.8)	295(40.2)	626(42.5)
<b>Race</b>			
Mixed Race <sup>†</sup>	708(95.8)	695(94.8)	1403(95.3)
White	5(0.7)	6(0.8)	11(0.7)
Black or African American	5(0.7)	5(0.7)	10(0.7)
Unknown	21(2.8)	27(3.7)	48(3.3)
<b>Age, years</b>			
>= 50 years	325(44.0)	318(43.4)	643(43.7)
<b>Age Descriptive Statistics</b>			
Median	50	49	50
IQR	17	18	18
<b>Body Mass Index (BMI)</b>			
<30 kg/m <sup>2</sup>	354(47.9)	360(49.1)	714(48.5)
>=30 kg/m <sup>2</sup>	372(50.3)	359(49.0)	731(49.7)
Unspecified	13(1.8)	14(1.9)	27(1.8)
<b>Time since onset of symptoms</b>			
0-3 days	318(43.0)	296(40.4)	614(41.7)
4-7 days	241(32.6)	249(34.0)	490(33.3)
Unspecified	180(24.3)	188(25.7)	368(25.0)
<b>Risk factors</b>			

Chronic cardiac disease	8(1.1)	8(1.1)	16(1.1)
Hypertension	106(14.4)	88(12.0)	194(13.2)
Chronic pulmonary disease	6(0.8)	3(0.4)	9(0.6)
Asthma	11(1.5)	16(2.2)	27(1.8)
Chronic kidney disease	2(0.3)	2(0.3)	4(0.3)
Rheumatologic disorder	1(0.1)	0(0.0)	1(0.1)
Chronic neurological disorder	8(1.1)	6(0.8)	14(1.0)
Diabetes mellitus: Type 1	25(3.4)	22(3.0)	47(3.2)
Diabetes mellitus: Type 2	103(14.0)	93(12.7)	196(13.3)
Obesity	2(0.3)	1(0.1)	3(0.2)
Any other risk factor(s) or co-morbidities	24(3.3)	19(2.6)	43(2.9)

515 **LEGEND:** †Self-identified as someone with mixed-race ancestry.

516 **Table 2:** Proportion of primary outcome events and relative risk of extended emergency room  
517 observation or hospitalization of fluvoxamine vs. placebo

	Intention-to-treat analysis			Modified intention-to-treat analysis		
	N	n (%)	Relative risk (95% CrI)	N	n (%)	Relative risk (95% CrI)
Fluvoxamine	739	77 (10.4 %)	0.71 [0.54; 0.93]	728	66(9.1 %)	0.68 [0.50; 0.91]
Placebo	733	108 (14.7 %)	1.00 (ref)	722	97(13.4 %)	1.00 (ref)
All	1472	185 (12.6%)	--	1450	163(11.2 %)	--

518 **LEGEND:** 95% CrI – Credible intervals

519

520 **Table 3:** Secondary outcomes of fluvoxamine vs placebo in the TOGETHER Trial

	<b>Fluvoxamine</b>	<b>Placebo</b>	<b>Estimated treatment effect (95% CI)</b>	<b>p-value</b>
<b>Viral clearance (Day 7)</b>	45/218 (21%)	57/217 (26%)	0.73 (0.47, 1.14) *	0.17
<b>Hospitalized for COVID</b>	74/739 (10.0%)	90/733 (12.3%)	0.79 (0.57, 1.10) *	0.17
<b>All-cause hospitalization</b>	74/739 (10.0%)	92/733 (12.6%)	0.77 (0.56, 1.07) *	0.12
<b>Time to hospitalization</b>	5 days [3 to 7]	5 days [3 to 7]	0.79 (0.58, 1.08) †	0.14
<b>Number of days of hospitalization</b>	7 days [5 to 12.5]	6 days [3 to 10.75]	1.22 (0.98, 1.53) ‡	0.07
<b>Emergency room visit for at least 6 hours</b>	6/739 (0.8%)	30/733 (4.1%)	0.19 (0.07, 0.43) *	<0.01
<b>Time to the emergency visit for at least 6 hours</b>	5.5 days [4.25 to 6.75]	6 days [3.25 to 8.75]	0.19 (0.08, 0.47) †	<0.01
<b>Death</b>	17/739 (2.3%)	24/733 (3.3%)	0.70 (0.36 to 1.30) *	0.26
<b>Time to death</b>	17 days [9 to 21]	14 days [8 to 20]	0.79 (0.58 to 1.08)	0.26
<b>Number of days on mechanical ventilator</b>	7 days [3 to 12]	6.5 days [3 to 12]	1.10 (0.70 to 1.73) ‡	0.67
<b>Adherence</b>	541/739 (73.2%)	609/733 (83.1%)	0.48 (0.36, 0.63) *	<0.01
<b>Grade 1 TEAE</b>	17/739 (2.3%)	5/733 (0.7%)	3.43 (1.35 to 10.47) *	0.02
<b>Grade 2 TEAE</b>	62/739 (8.4%)	74/733 (9.4%)	0.82 (0.57 to 1.16) *	0.26
<b>Grade 3 TEAE</b>	34/739 (4.2%)	43/733 (4.6%)	0.77 (0.48 to 1.23) *	0.28
<b>Grade 4 TEAE</b>	18/739 (2.3%)	20/733 (2.2%)	0.89 (0.46 to 1.70) *	0.72
<b>Grade 5 TEAE</b>	18/739 (2.2%)	25/733 (2.3%)	0.71(0.38 to 1.30) *	0.27

521 **LEGEND:** TEAE: Treatment Emergent Adverse Event

522 Summary statistics are presented as n/N or median (IQR) unless otherwise stated.

523 \* Unadjusted odd ratio

524 † Unadjusted hazard ratio.

525 ‡Exponentiated unadjusted estimates from a log-transformed linear regression.

526